10x, Harvard settle genomics patent dispute with Vizgen during trial (updated)

10x Genomics

06/02/2025 21:06

(Adds comment from Vizgen in paragraph 4)
    By Blake Brittain
       Feb 6 (Reuters) - Genomics company 10x  TXG.O  and
Harvard University have agreed to resolve a patent lawsuit
against 10x's rival Vizgen four days into a scheduled two-week
trial, according to a Thursday filing in Delaware federal court.
    10x and Harvard had accused Vizgen of infringing patents
related to gene analysis. Vizgen countersued the company and
university for allegedly breaking a contract with the U.S.
National Institutes of Health by monopolizing their 
technology. 
    10x, Harvard and Vizgen told the court they would dismiss
the case with prejudice, which means the claims and
counterclaims cannot be refiled. 
    Representatives for both sides in the case said they were
pleased to have resolved the dispute. 
    10x sued Vizgen in 2022 for allegedly infringing patents
covering its Xenium In Situ gene-analysis platform. 10x licenses
the patents from Harvard, and the university is also a
plaintiff.
    10x and Harvard requested at least $9.2 million in
infringement damages, while Vizgen was seeking between $91
million and $374 million in its antitrust case, according to a
court filing.
    Antitrust allegations against 10x and Harvard from life
sciences company Bruker  BRKR.O  remain ongoing in a related
patent lawsuit.
    The case is 10x Genomics Inc v. Vizgen Inc, U.S. District
Court for the District of Delaware, No. 1:22-cv-00595.
    For 10x: Matthew Powers of Tensegrity Law Group
    For Harvard: Geoffrey Raux of Foley & Lardner
    For Vizgen: David Bilsker of Quinn Emanuel Urquhart &
Sullivan
    
    Read more:
    10x, Harvard must face antitrust claims in gene-analysis
patent cases

 (Reporting by Blake Brittain in Washington)